Healthcare Stocks Lead: IMMP Surges 1573%, IOVA Jumps 31.7% After EPS Revisions
Immutep (IMMP) skyrocketed 1573.1% to $4.35 after its next-year EPS growth estimate was set at 25.5% following detection on September 27. Iovance Biotherapeutics (IOVA) gained 31.7% to $14.22 after raising FY2026 revenue guidance to $410-$420 million on September 29, reinforcing a 52.0% EPS growth estimate detected on September 24. Other top performers include NNBR (+25.3%), PXS (+20.0%), and LITE (+17.8%), all driven by upward EPS revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| IMMP | Healthcare | 2026-09-27 | N/A | +1573.1% |
| IOVA | Healthcare | 2026-09-24 | N/A | +31.7% |
| NNBR | Industrials | 2026-09-24 | +1.8pp | +25.3% |
| PXS | Energy | 2026-09-29 | N/A | +20.0% |
| LITE | Technology | 2026-09-28 | N/A | +17.8% |
Why did IMMP stock jump in October 2026?
IMMP jumped 1573.1% (from $0.26 to $4.35) after its next-year EPS growth estimate was set at 25.5% on September 27.
The micro-cap healthcare stock, which trades as an ADR for Australian biotech Immutep, caught the screener's attention when its forward EPS growth estimate was revised upward, signaling expected profitability improvement. With no company-specific news in the window, the massive rally likely reflects broader sector momentum in immuno-oncology and speculative interest in low-priced biotechs with promising pipelines. The extreme price gain underscores how quickly small-cap healthcare names can move when earnings expectations shift.
IMMP EPS revision history → · Screener snapshot from 2026-09-27 →
FAQ: IMMP
Why did IMMP stock jump in September 2026?
IMMP surged 1573.1% from $0.26 to $4.35 after its next-year EPS growth estimate was set at 25.5% on September 27, 2026, according to our EPS revision screener.
Is IMMP a buy after the rally?
IMMP's 1573% rally leaves it highly speculative; investors should weigh the 25.5% next-year EPS growth estimate against the lack of recent news and the stock's micro-cap volatility.
What is IMMP's EPS growth estimate?
Immutep's next-year EPS growth estimate stands at 25.5%, as detected on September 27, 2026.
Why did IOVA stock jump in October 2026?
IOVA jumped 31.7% (from $10.80 to $14.22) after analysts raised its next-year EPS growth estimate to 52.0% on September 24.
The move was reinforced on September 29 when Iovance raised its FY2026 revenue outlook to $410-$420 million, up from $350-$370 million, citing record Q2 product revenue of $99.3 million and strong demand for its cancer therapies Amtagvi and Proleukin. The new guidance midpoint of $415 million cleared consensus of $402.8 million, signaling accelerating commercial momentum. Shares hit over two-year highs as the company expanded its authorized treatment center network to approximately 100 locations, with plans to reach at least 110 by year-end.
IOVA EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: IOVA
Why did IOVA stock jump in September 2026?
IOVA jumped 31.7% to $14.22 after raising FY2026 revenue guidance to $410-$420 million on September 29, following an EPS growth estimate revision to 52.0% on September 24.
What caused Iovance's revenue outlook increase?
Iovance raised its FY2026 revenue outlook due to record Q2 product revenue of $99.3 million and strong demand for Amtagvi and Proleukin, leading to a $55 million midpoint increase.
Is IOVA a buy after the rally?
IOVA's 31.7% rally reflects improved fundamentals with a 52.0% EPS growth estimate and raised guidance; however, investors should consider the competitive oncology landscape and upcoming Q3 results in November.
Why did NNBR stock jump in October 2026?
NNBR jumped 25.3% (from $3.60 to $4.51) after its next-year EPS growth estimate was revised upward from 71.0% to 72.7% on September 24.
The industrial company, which operates in precision engineering and components, saw its earnings outlook improve by 1.8 percentage points, catching the screener's attention. With no specific news in the window, the rally likely reflects broader industrial sector strength or expectations of operational improvements. The magnitude of the EPS growth estimate—now 72.7%—suggests analysts anticipate significant bottom-line expansion ahead.
NNBR EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: NNBR
Why did NNBR stock jump in September 2026?
NNBR rose 25.3% to $4.51 after its next-year EPS growth estimate was revised from 71.0% to 72.7% on September 24, 2026, per our screener.
What is NNBR's EPS growth estimate?
NN Inc's next-year EPS growth estimate is 72.7%, following a 1.8 percentage point upward revision on September 24, 2026.
Is NNBR a buy after the rally?
NNBR's 25.3% gain reflects a positive EPS revision and a 72.7% growth estimate, but without recent news, investors should monitor upcoming earnings for confirmation of operational improvements.
Why did PXS stock jump in October 2026?
PXS jumped 20.0% (from $6.44 to $7.73) after its next-year EPS growth estimate was set at 39.0% on September 29.
The energy sector company, which operates in the tanker shipping industry, benefited from an upward revision in earnings expectations. With no company-specific news, the move likely aligns with broader energy market dynamics, such as rising tanker rates or improving demand outlook. The 39.0% EPS growth estimate indicates analysts see substantial profit expansion ahead for Pyxis Tankers.
PXS EPS revision history → · Screener snapshot from 2026-09-29 →
FAQ: PXS
Why did PXS stock jump in September 2026?
PXS gained 20.0% to $7.73 after its next-year EPS growth estimate was set at 39.0% on September 29, 2026, as detected by our EPS revision screener.
What is PXS's EPS growth estimate?
Pyxis Tankers' next-year EPS growth estimate is 39.0%, based on the screener detection on September 29, 2026.
Is PXS a buy after the rally?
PXS's 20% rally is driven by a 39.0% EPS growth estimate and energy sector momentum; however, tanker shipping remains cyclical, so investors should assess freight rate trends.
Why did LITE stock jump in October 2026?
LITE jumped 17.8% (from $921.32 to $1085.42) after its next-year EPS growth estimate was set at 57.6% on September 28.
The technology company, a leading provider of optical and photonic solutions, caught the screener's attention with its strong earnings growth forecast. While no direct news was found, the stock may have benefited from analyst upgrades in the tech sector, as seen in recent Wall Street calls. The 57.6% EPS growth estimate suggests confidence in Lumentum's ability to capitalize on demand for optical components in data centers and telecommunications.
LITE EPS revision history → · Screener snapshot from 2026-09-28 →
FAQ: LITE
Why did LITE stock jump in September 2026?
LITE rose 17.8% to $1085.42 after its next-year EPS growth estimate was set at 57.6% on September 28, 2026, according to our EPS revision screener.
What is LITE's EPS growth estimate?
Lumentum Holdings' next-year EPS growth estimate is 57.6%, as detected on September 28, 2026.
Is LITE a buy after the rally?
LITE's 17.8% gain is backed by a 57.6% EPS growth estimate and strong demand for optical components; however, the stock's high price may warrant caution after such a move.
Today's top performers highlight the power of upward EPS revisions, particularly in healthcare and industrials, where improving earnings outlooks drove significant gains. The market's positive reaction to Iovance's raised guidance underscores the importance of fundamental catalysts in sustaining rallies.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →